Loading clinical trials...
Loading clinical trials...
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Conditions
Interventions
OPT-302
ranibizumab
+1 more
Locations
108
United States
Opthea Investigational Site
Phoenix, Arizona, United States
Opthea Investigational Site
Phoenix, Arizona, United States
Opthea Investigational Site
Beverly Hills, California, United States
Opthea Investigational Site
Encino, California, United States
Opthea Investigational Site
Palm Desert, California, United States
Opthea Investigational Site
Redlands, California, United States
Start Date
November 6, 2017
Primary Completion Date
May 14, 2019
Completion Date
May 14, 2019
Last Updated
January 12, 2021
NCT07308639
NCT06439576
NCT05562947
NCT05904028
NCT06213038
NCT06492863
Lead Sponsor
Opthea Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions